In COAD, 15.1% of later-onset cases, compared to only 2.2% of young adult cases, harbored mutations in BRAF V600E, which was druggable with two combination therapies (Panitumumab + Encorafenib and Encorafenib + Cetuximab); these fractions account for all COAD cases with level A on-label treatment options in both cohorts (Figures 7A, 7B, and S7A). Here, BRAF is linked to colon adenocarcinoma.